Several studies have reported the potential of peripheral blood-based and tumor-based biomarkers, such as TMB score, gene signatures, PD-L1 expression, phenotypes of TILs, and multiplex immunohistochemistry assays for qualifying TILs (28–31). This evidence concerns the gene CD274 and neoplasm.